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Cost-effectiveness of paliperidone palmitate versus other antipsychotics for the treatment of schizophrenia in France RESULTS 
RESULTS

Modelling approach:
• A Markov model was developed to estimate the cost-utility and the cost per relapse avoided associated with PLAI, by simulating the progression of schizophrenic patients through four health states and up to three lines of treatment.
• Costs, quality-adjusted life years (QALYs) and number of relapses were assessed over five years based on three-month cycles, and discounted at 4%, from a health insurance perspective.
Model Population and Structure
• Patients were assumed to be stabilised after a clinical decompensation and entered the model in an initiation phase (in blue), followed by a relapse prevention phase (in white) in the case of treatment success.
• Patients could progress through four health states:
• Stable treated (with or without adverse events)
• Stable non-treated • Relapse (with or without hospitalisation)
• Death
Comparators
• Relevant comparators were identified by French clinical experts, includeding risperidone LAI (RLAI), aripiprazole LAI (ALAI), olanzapine LAI (OLAI), haloperidol decanoate (HLAI) and oral olanzapine (OO).
• The model was developed to focus on first-line regimens, therefore subsequent lines were similar regardless of the previous line. The second line was composed of PLAI (25%), RLAI (25%), ALAI (25%) and OLAI (25%). In third line, patient received clozapine based on treatment guidelines. [6] [7] [8] • Inputs data for the model are presented in Table 1 .
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Input Description
Baseline characteristics Population age (38 years), sex (68% male) were based on CGS observational data. [5] Probabilities of relapse Initiation phase: the 3-month probabilities of relapse were based on a 13-week clinical trial for PLAI (0.0659) and RLAI (0.0701), and odds ratios (ORs) from a meta-analysis were applied for other treatments. [9;10] Prevention phase: the 3-month probabilities of relapse were based on a French observational study (PLAI=RLAI=ALAI=OLAI=0.0825) and relative risks (RR) were applied for other comparators (RR(RLAI/injectable 1 st G. AP)=0.53) ; RR(RLAI/oral 2 nd G. AP)=0.60). [5] Probabilities of switch and discontinuation
Initiation phase: the 3-month probabilities were based on a 13-week clinical trial for PLAI (switch=0.0329 ; stop=0.1450) and RLAI (switch=0.0163 ; stop=0.1452), and ORs from a meta-analysis were applied for other treatments. [9;10] Prevention phase: the 3-month probabilities were derived from a long-term clinical trial for PLAI (switch=0.0042 ; stop=0.0387) and hypotheses of equivalence for other comparators were made. [11] Probabilities of adverse events
The 3-month probabilities were based on clinical trials, meta-analysis and summary product characteristics (SPC).[9;14;15]
Cost of treatments
The daily costs of treatment were based on the French National Formulary (FNF) according to the recommended posology (specific to the initiation phase).
[16] An aggregated cost was applied for the second line composed by PLAI, RLAI, ALAI and OLAI (initiation: €1,064/3-months for outpatients and €613/3-months for inpatient; prevention: €917/3-months).
Cost of hospitalisation
The daily cost of hospitalisation was based on French governmental data. (EPS= -0.049 ; tardive dyskinesia= -0.049; diabetes:= -0.038; weight gain ≥7% = -0.024)
• PLAI was the optimal strategy in terms of cost per QALY gained and relapse avoided.
• PLAI was found to be the least expensive LAI antipsychotic from a French payer perspective.
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• Adverse events included extrapyramidal symptoms (EPS), tardive dyskinesia, diabetes and weight gain (≥7%).
• There were three causes of treatment interruption: relapse (due to lack of efficacy), switch (due to lack of tolerance) and discontinuation (due to patient decision). • PLAI was the least costly LAI and was associated with an additional cost of €514 compared to OO over 5 years.
Results
Costs
• RLAI and PLAI were associated with the highest number of QALYs.
• PLAI was associated with the lowest number of relapses except vs. OLAI (1.4366 vs 1.4333).
• PLAI dominated ALAI, OLAI and HLAI • PLAI was associated with an ICER of €2,474 per QALY gained compared to OO. 
